FDAnews
www.fdanews.com/articles/203240-pfizers-xeljanz-shows-promise-for-treating-covid-19-pneumonia

Pfizer’s Xeljanz Shows Promise for Treating COVID-19 Pneumonia

June 21, 2021

Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz (tofacitinib) reduced the incidence of death or respiratory failure among hospitalized patients with COVID-19 pneumonia in a Brazilian study.

The cumulative incidence of death or respiratory failure through day 28 of the illness was 18.1 percent (26 of 144) with tofacitinib compared to 29 percent (42 of 145) with placebo, according to study data just reported in the New England Journal of Medicine.

The trial of tofacitinib, an oral Janus kinase inhibitor, was a collaboration between Pfizer and the academic research organization at the Hospital Israelita Albert Einstein in Sao Paulo.

View today's stories